Moderate Evidence
Research Overview
Zelenectide Pevedotin Research for Breast Cancer
An evidence-based overview of research examining Zelenectide Pevedotin in the context of breast cancer. This page synthesizes findings from peer-reviewed literature.
Research Summary
Evaluated in Phase 1/2 expansion based on moderate-high Nectin-4 expression (50-70%). Preliminary ORR ~25-30%. Early stage development for this indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Zelenectide Pevedotin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.